全文获取类型
收费全文 | 939篇 |
免费 | 79篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 33篇 |
妇产科学 | 2篇 |
基础医学 | 130篇 |
口腔科学 | 4篇 |
临床医学 | 73篇 |
内科学 | 444篇 |
皮肤病学 | 13篇 |
神经病学 | 16篇 |
特种医学 | 144篇 |
外科学 | 47篇 |
综合类 | 31篇 |
预防医学 | 15篇 |
眼科学 | 6篇 |
药学 | 26篇 |
中国医学 | 3篇 |
肿瘤学 | 36篇 |
出版年
2023年 | 3篇 |
2022年 | 3篇 |
2021年 | 5篇 |
2020年 | 10篇 |
2019年 | 9篇 |
2018年 | 8篇 |
2017年 | 3篇 |
2016年 | 13篇 |
2015年 | 14篇 |
2014年 | 14篇 |
2013年 | 32篇 |
2012年 | 36篇 |
2011年 | 42篇 |
2010年 | 29篇 |
2009年 | 30篇 |
2008年 | 54篇 |
2007年 | 41篇 |
2006年 | 53篇 |
2005年 | 39篇 |
2004年 | 24篇 |
2003年 | 40篇 |
2002年 | 35篇 |
2001年 | 33篇 |
2000年 | 33篇 |
1999年 | 30篇 |
1998年 | 53篇 |
1997年 | 40篇 |
1996年 | 23篇 |
1995年 | 15篇 |
1994年 | 19篇 |
1993年 | 21篇 |
1992年 | 13篇 |
1991年 | 15篇 |
1990年 | 18篇 |
1989年 | 15篇 |
1988年 | 16篇 |
1987年 | 19篇 |
1986年 | 16篇 |
1985年 | 18篇 |
1984年 | 9篇 |
1983年 | 10篇 |
1982年 | 11篇 |
1981年 | 11篇 |
1980年 | 9篇 |
1979年 | 3篇 |
1978年 | 9篇 |
1977年 | 8篇 |
1976年 | 5篇 |
1975年 | 4篇 |
1972年 | 3篇 |
排序方式: 共有1029条查询结果,搜索用时 9 毫秒
21.
E. Keystone G. R. Burmester R. Furie J. E. Loveless P. Emery J. Kremer P. P. Tak M. S. Broder E. Yu M. Cravets F. Magrini F. Jost 《Arthritis care & research》2008,59(6):785-793
Objective
To assess the effects of treatment with rituximab plus methotrexate on patient‐reported outcomes in patients with active rheumatoid arthritis (RA) who experienced inadequate response to anti–tumor necrosis factor therapy.Methods
Patients with active RA were randomly assigned to rituximab (1,000 mg on days 1 and 15) or placebo. The primary end point was the proportion of patients with an American College of Rheumatology 20% response at week 24. Additional goals were to assess treatment effects on pain, fatigue, functional disability, health‐related quality of life, and disease activity by comparing mean changes between groups. The analysis was conducted in the intent‐to‐treat population. The proportion of patients who achieved the minimum clinically important difference on the Health Assessment Questionnaire (HAQ) disability index (DI), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT‐F), and Short Form 36 (SF‐36) was determined.Results
Rituximab patients had statistically significantly greater pain relief. The FACIT‐F showed significantly greater improvement in rituximab patients than placebo patients from weeks 12 through 24. Mean improvement from baseline in functional disability (measured by the HAQ DI) was significantly greater in rituximab patients from weeks 8 to 24. The mean ± SD change from baseline for the SF‐36 Physical Component Score was 6.64 ± 8.74 for rituximab patients and 1.48 ± 7.32 for placebo patients (P < 0.0001). The mean change from baseline for the SF‐36 Mental Component Score was 5.32 ± 12.41 for rituximab patients and 2.25 ± 12.23 for placebo patients (P = 0.0269).Conclusion
Rituximab produced rapid, clinically meaningful, and statistically significant improvements in patient‐reported pain, fatigue, functional disability, health‐related quality of life, and disease activity. These effects were sustained throughout the study. 相似文献22.
The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis 总被引:10,自引:0,他引:10
Bläss S Union A Raymackers J Schumann F Ungethüm U Müller-Steinbach S De Keyser F Engel JM Burmester GR 《Arthritis and rheumatism》2001,44(4):761-771
OBJECTIVE: The ubiquitously expressed intracellular protein formerly designated p68 has been identified as autoantigen at both the antibody and the T cell level in rheumatoid arthritis (RA). METHODS: We used 2 independent approaches, Edman degradation and matrix-assisted laser desorption ionization-time-of-flight mass spectrometry, to characterize p68, and we compared its features with those of the endoplasmic reticulum stress protein BiP. RESULTS: In synovial sections from RA patients, BiP was highly overexpressed as compared with control sections. Under in vitro stress conditions, BiP was found to translocate to the nucleus and the cell surface. BiP-specific autoantibodies were present in 63% of 400 RA patients, in 7% of 200 patients with other rheumatic diseases, and in none of the healthy subjects. Thus, BiP-specific autoantibodies represent a new diagnostic marker in RA. Furthermore, we found that BiP-specific T cell reactivity was altered in RA. In healthy individuals and patients with other rheumatic diseases, BiP-reactive T cells were undetectable. In RA, overt T cell reactivity to BiP was observed or could be induced by specifically blocking antigen presentation to potentially regulatory T cells. CONCLUSION: Since overexpression of BiP has been shown to decrease the sensitivity of cells to killing by cytotoxic T cells, BiP overexpression and BiP-specific autoimmunity may be involved in the pathogenesis of RA. 相似文献
23.
24.
JK Dickson A Davies S Rahman C Sethu JRO Smith A Orlando D Ayers 《Annals of the Royal College of Surgeons of England》2015,97(1):52-55
IntroductionDissection of regional lymph nodes (RLNs) can lead to significant morbidity and a high prevalence of complications. Published guidance states that these procedures should be carried out by surgeons who are members of a specialist skin multidisciplinary team who carry out a combined minimum of 15 axillary/groin dissections per year. However, there is little evidence to guide this minimum figure of procedures. We report on the burden of service provision and prevalence of complications across the South West of England and Wales.MethodsA 12-month review of dissections of RLNs for skin cancer was undertaken covering five Plastic Surgery Units with a collective catchment of 8.4 million people. Detailed data were collected on patient demographics, pathology, timing of surgery, and prevalence of complications.ResultsA total of 163 dissections were carried out. Forty-three per cent of patients experienced one or more complication. In that 12-month period, an average of 8 axillary/groin dissections was carried out per surgeon. A funnel plot demonstrated that the prevalence of complications for individual surgeons was within the limit of the plot but, in many cases, this was based only on a relatively small number of procedures per consultant. If surgeons carried out 10 procedures per year, the upper and lower limits on the plot were 73% and 11%, respectively.ConclusionsFunnel plots can provide a useful guide as to whether the prevalence of complications for procedures for individual surgeons lies within acceptable limits. Based on these results, 10 procedures per consultant per year should be sufficient to enable meaningful assessment of the prevalence of complications. 相似文献
25.
Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls 总被引:6,自引:0,他引:6 下载免费PDF全文
Jacobi AM Rohde W Volk HD Dörner T Burmester GR Hiepe F 《Annals of the rheumatic diseases》2001,60(3):242-247
OBJECTIVES: Recent evidence suggests that prolactin (PRL) plays a part in the pathogenesis of systemic lupus erythematosus (SLE). Because B cell hyperreactivity and autoantibodies are characteristic hallmarks of SLE, this study aimed at assessing the impact of this pituitary hormone on IgG production by stimulating peripheral blood mononuclear cells (PBMC) with PRL. METHODS: PBMC from 11 patients with SLE assessed by the ECLAM score and eight healthy controls were incubated with PRL and cultured for seven days. IgG production was measured by enzyme linked immunosorbent assay (ELISA). RESULTS: Spontaneous IgG production of SLE PBMC was significantly enhanced compared with that found in healthy controls. After PRL stimulation, the IgG concentrations of supernatants from SLE PBMC were significantly higher than those of unstimulated PBMC (median 394 ng/ml). Of note, the physiological concentration of PRL (20 ng/ml) induced IgG production more effectively (median 1139 ng/ml) than PRL at 100 ng/ml (median 1029 ng/ml). In contrast, preincubation with PRL did not stimulate IgG production in normal PBMC. A significant correlation between PRL induced IgG production and the disease activity (ECLAM) of the patients with SLE was seen. Moreover, the maximum amount of PRL induced IgG depended on the serum PRL concentrations of the patients with SLE. CONCLUSIONS: The results suggest that PBMC from patients with SLE have an extraordinarily high susceptibility to PRL, showing the most striking effect at a concentration usually found in vivo. This indicates a potential role for mild hyperprolactinaemia in the pathogenesis of SLE, influencing both IgG production and disease activity. 相似文献
26.
27.
28.
Wakefield RJ D'Agostino MA Naredo E Buch MH Iagnocco A Terslev L Ostergaard M Backhaus M Grassi W Dougados M Burmester GR Saleem B de Miguel E Estrach C Ikeda K Gutierrez M Thompson R Balint P Emery P 《Annals of the rheumatic diseases》2012,71(6):799-803
For patients with rheumatoid arthritis (RA), remission can be achieved with tight control of inflammation and early use of disease modifying agents. The importance of remission as an outcome has been recently highlighted by European League Against Rheumatism recommendations. However, remission when defined by clinical remission criteria (disease activity score, simplified disease activity index, etc) does not always equate to the complete absence of inflammation as measured by new sensitive imaging techniques such as ultrasound (US) . There is evidence that imaging synovitis is frequently found in these patients and associated with adverse clinical and functional outcomes. This article reviews the data regarding remission, ultrasound imaging and outcomes in patients with RA to provide the background to a consensus statement from an international collaboration of ultrasonographers and rheumatologists who have recently formed a research network--the Targeted Ultrasound Initiative (TUI) group. The statement proposes that targeting therapy to PD activity provides superior outcomes compared with treating to clinical targets alone and introduces the rationale for a new randomised trial using targeted ultrasound in RA. 相似文献
29.
Gossec L Smolen JS Gaujoux-Viala C Ash Z Marzo-Ortega H van der Heijde D FitzGerald O Aletaha D Balint P Boumpas D Braun J Breedveld FC Burmester G Cañete JD de Wit M Dagfinrud H de Vlam K Dougados M Helliwell P Kavanaugh A Kvien TK Landewé R Luger T Maccarone M McGonagle D McHugh N McInnes IB Ritchlin C Sieper J Tak PP Valesini G Vencovsky J Winthrop KL Zink A Emery P;European League Against Rheumatism 《Annals of the rheumatic diseases》2012,71(1):4-12
30.